Zacks Investment Research cut shares of Beigene (NASDAQ:BGNE) from a hold rating to a sell rating in a research note released on Monday morning.
According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “
Several other research firms also recently weighed in on BGNE. Morgan Stanley reiterated an overweight rating and issued a $95.00 price target (up from $87.00) on shares of Beigene in a research report on Friday, October 6th. Maxim Group set a $120.00 price objective on shares of Beigene and gave the stock a buy rating in a research note on Wednesday, January 3rd. ValuEngine cut shares of Beigene from a hold rating to a sell rating in a research note on Wednesday, January 3rd. BidaskClub raised shares of Beigene from a hold rating to a buy rating in a research note on Friday, January 5th. Finally, Cowen reissued a buy rating on shares of Beigene in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $96.67.
Beigene (NASDAQ BGNE) traded up $1.44 on Monday, reaching $103.28. 140,662 shares of the company’s stock traded hands, compared to its average volume of 180,956. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. Beigene has a fifty-two week low of $31.70 and a fifty-two week high of $118.95. The company has a market capitalization of $4,700.00 and a P/E ratio of -78.84.
Beigene (NASDAQ:BGNE) last released its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $2.31. The business had revenue of $220.21 million during the quarter, compared to the consensus estimate of $1.55 million. During the same quarter in the previous year, the business posted ($1.08) earnings per share. research analysts expect that Beigene will post -2.04 earnings per share for the current year.
In related news, CMO Jane Huang sold 600 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $85.00, for a total transaction of $51,000.00. Following the completion of the transaction, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at $22,516,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Oyler sold 150,957 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the transaction, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at $39,597,225.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 483,482 shares of company stock valued at $42,139,474. Corporate insiders own 19.90% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Employees Retirement System of Texas purchased a new position in Beigene during the second quarter valued at $2,855,000. Alps Advisors Inc. grew its stake in Beigene by 15.9% during the third quarter. Alps Advisors Inc. now owns 41,739 shares of the company’s stock valued at $4,318,000 after acquiring an additional 5,732 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Beigene by 25.0% during the second quarter. Parametric Portfolio Associates LLC now owns 13,496 shares of the company’s stock valued at $607,000 after acquiring an additional 2,700 shares in the last quarter. Belpointe Asset Management LLC purchased a new position in Beigene during the third quarter valued at $1,642,000. Finally, Westpac Banking Corp purchased a new position in Beigene during the third quarter valued at $662,000. 55.32% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://ledgergazette.com/2018/01/12/beigene-bgne-downgraded-by-zacks-investment-research.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.